Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Efficiency
Asset turnover0.7×0.6×
Liquidity
Current ratio4.6×+0.6×2.3×-1.9×-0.9×2.9×-1.0×0.0×
Quick ratio4.3×+0.6×2.1×-1.8×2.7×-0.8×2.7×-0.9×3.7×0.0×
Cash ratio0.9×+0.5×0.7×-0.8×0.7×+0.4×0.6×0.0×0.4×-0.3×
Leverage
Debt-to-equity0.1×0.0×0.2×0.0×0.2×-0.1×0.2×-0.1×0.2×-0.1×
Debt-to-assets0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×
Valuation
Market capitalization$2.28B-63.1%$2.26B-80.6%$2.02B-82.9%$1.87B-87.4%$6.19B-49.1%
Enterprise value$2.02B-67.2%$1.66B-84.5%$1.62B-86.4%$1.57B-89.3%$6.16B-48.6%
Price / sales
Price / book1.5×-3.9×-5.6×1.5×-8.1×1.4×-12.4×5.4×-7.2×
EV / sales0.9×0.8×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Sarepta Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Sarepta Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.